

5 February 2024

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Directorate Change and Appointment of Head of Development**

- Dr Sally Adams to retire as an Executive Director of the Board and as Chief Development Officer
- Dr Callum Scott has been appointed as Head of Development

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that Dr Sally Adams is retiring as an Executive Director of the Board and as Chief Development Officer. Dr Callum Scott has been appointed as the new Head of Development, effective immediately, and Sally will remain with the Company part time for 6 months to ensure a smooth and effective transition of responsibilities.

Dr Scott brings over 15 years of experience in vaccine research and development. Previously, he held the role of Technical Transfer & Formulation Development Manager at UK biotech firm Allergy Therapeutics (AIM: AGY) where he led all CMC (Chemistry, Manufacturing and Controls)/product development activities relating to their VLP Peanut project through Phases 1-3 including IND approvals. Dr Scott holds a PhD in Molecular Microbiology and a BSc in Biochemistry, both from Heriot-Watt University.

**Prof Lindy Durrant, Chief Executive Officer of Scancell, commented:** *"Firstly, on behalf of the Scancell Board, I would like to express our sincere gratitude to Sally for her expertise and support over the last 15 years, both on the Board and leading clinical development. She has been instrumental in establishing a highly motivated development team and has worked tirelessly to bring our highly differentiated and valuable cancer vaccines through to the clinic. We wish her all the best for the future.*

*"I would also like to warmly welcome Callum to Scancell. His understanding of the challenges involved in developing, registering, and commercialising novel biologics will be of great value to Scancell as we continue to develop our lead assets SCIB1 and Modi-1 through later stage clinical development."*

**Dr Sally Adams, Chief Development Officer, said:** *"It has been a privilege to work with Lindy and the Scancell team for the last 15 years, helping to develop successful manufacturing processes and quality systems and to take three products into the clinic. The recent clinical successes with SCIB1 and Modi-1 have been the culmination of a huge team effort across the Company, and I have every confidence that these results will be built upon in the future. I wish Lindy and the Company every success."*

**Dr Callum Scott, Head of Development, commented:** *"Joining Scancell when SCIB1 and Modi-1 cancer vaccines are making highly promising clinical progress is very exciting, with further data from the SCOPE study expected in mid-2024 and ModiFY trial later this year. I look forward to contributing to the rapid advancement of these innovative and high-value assets through the clinic and towards commercialisation and working with Lindy and the Scancell team."*

**For further information, please contact:**

**Scancell Holdings plc** +44 (0) 20 3709 5700  
Dr Jean-Michel Cosséry, Non-Executive Chairman  
Professor Lindy Durrant, CEO

**Stifel Nicolaus Europe Limited** (Nominated Adviser and Joint Broker) +44 (0) 20 7710 7600  
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)  
Nick Adams/Nick Harland (Corporate Broking)

**WG Partners LLP (Joint Broker)** +44 (0) 20 3705 9330  
David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

**Panmure Gordon (UK) Limited** (Joint Broker)  
Freddy Crossley/Emma Earl (Corporate Finance)  
Rupert Dearden (Corporate Broking)

+44 (0) 20 7886 2500

**ICR Consilium**  
Mary-Jane Elliott/Matthew Neal/Chris Welsh

+44 (0) 20 3709 5700  
[scancell@consilium-comms.com](mailto:scancell@consilium-comms.com)

## **About Scancell**

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope<sup>®</sup> and ImmunoBody<sup>®</sup> for vaccines and GlyMab<sup>®</sup> and AvidiMab<sup>®</sup> for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope<sup>®</sup> and ImmunoBody<sup>®</sup>) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab<sup>®</sup>) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab<sup>®</sup>).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>